×
About 2,880 results

ALLMedicine Hypophosphatemia Center

Research & Reviews  1,289 results

Surgical Treatment for Severe Fixed Hyperkyphosis in an Adult Patient Suffering From An...
https://doi.org/10.1097/BSD.0000000000001011
Clinical Spine Surgery; Wolfram JM, Zitt E et. al.

May 21st, 2020 - Ankylosing spondylitis and hereditary hypophosphatemia with long-term high dose supplementation of phosphorous and calcitriol can both lead to severe structural abnormalities of the vertebrae. Impairment of spinal mobility and spinal deformity may...

Fibroblast growth factor receptor as a potential candidate for phosphate sensing.
https://doi.org/10.1097/MNH.0000000000000618
Current Opinion in Nephrology and Hypertension; Takashi Y, Fukumoto S

May 19th, 2020 - Phosphate plays essential roles in many biological processes. Serum phosphate level needs to be regulated because hypophosphatemia and hyperphosphatemia cause rickets/osteomalacia and ectopic calcification, respectively. Fibroblast growth factor (...

Rare musculoskeletal diseases in adults: a research priority setting partnership with t...
https://doi.org/10.1186/s13023-020-01398-5
Orphanet Journal of Rare Diseases; Mickute G, Staley K et. al.

May 18th, 2020 - Osteogenesis imperfecta, fibrous dysplasia/McCune-Albright syndrome and X-linked hypophosphatemia are three rare musculoskeletal diseases characterised by bone deformities, frequent fractures and pain. Little high-quality research exists on approp...

Bone and mineral metabolism in children with nephropathic cystinosis compared to other ...
https://doi.org/10.1210/clinem/dgaa267
The Journal of Clinical Endocrinology and Metabolism; Ewert A, Leifheit-Nestler M et. al.

May 15th, 2020 - Children with nephropathic cystinosis (NC) show persistent hypophosphatemia, due to Fanconi syndrome, as well as mineral and bone disorders related to chronic kidney disease (CKD), but systematic analyses are lacking. To compare biochemical parame...

Congenital Conditions of Hypophosphatemia Expressed in Adults.
https://doi.org/10.1007/s00223-020-00695-2
Calcified Tissue International; Marcucci G, Brandi ML

May 13th, 2020 - The main congenital conditions of hypophosphatemia expressed in adulthood include several forms of hereditary hypophosphatemic rickets and a congenital disorder of vitamin D metabolism characterized by osteomalacia and hypophosphatemia in adult pa...

see more →

Drugs  111 results see all →

Clinicaltrials.gov  1,439 results

Surgical Treatment for Severe Fixed Hyperkyphosis in an Adult Patient Suffering From An...
https://doi.org/10.1097/BSD.0000000000001011
Clinical Spine Surgery; Wolfram JM, Zitt E et. al.

May 21st, 2020 - Ankylosing spondylitis and hereditary hypophosphatemia with long-term high dose supplementation of phosphorous and calcitriol can both lead to severe structural abnormalities of the vertebrae. Impairment of spinal mobility and spinal deformity may...

Fibroblast growth factor receptor as a potential candidate for phosphate sensing.
https://doi.org/10.1097/MNH.0000000000000618
Current Opinion in Nephrology and Hypertension; Takashi Y, Fukumoto S

May 19th, 2020 - Phosphate plays essential roles in many biological processes. Serum phosphate level needs to be regulated because hypophosphatemia and hyperphosphatemia cause rickets/osteomalacia and ectopic calcification, respectively. Fibroblast growth factor (...

Rare musculoskeletal diseases in adults: a research priority setting partnership with t...
https://doi.org/10.1186/s13023-020-01398-5
Orphanet Journal of Rare Diseases; Mickute G, Staley K et. al.

May 18th, 2020 - Osteogenesis imperfecta, fibrous dysplasia/McCune-Albright syndrome and X-linked hypophosphatemia are three rare musculoskeletal diseases characterised by bone deformities, frequent fractures and pain. Little high-quality research exists on approp...

Bone and mineral metabolism in children with nephropathic cystinosis compared to other ...
https://doi.org/10.1210/clinem/dgaa267
The Journal of Clinical Endocrinology and Metabolism; Ewert A, Leifheit-Nestler M et. al.

May 15th, 2020 - Children with nephropathic cystinosis (NC) show persistent hypophosphatemia, due to Fanconi syndrome, as well as mineral and bone disorders related to chronic kidney disease (CKD), but systematic analyses are lacking. To compare biochemical parame...

Congenital Conditions of Hypophosphatemia Expressed in Adults.
https://doi.org/10.1007/s00223-020-00695-2
Calcified Tissue International; Marcucci G, Brandi ML

May 13th, 2020 - The main congenital conditions of hypophosphatemia expressed in adulthood include several forms of hereditary hypophosphatemic rickets and a congenital disorder of vitamin D metabolism characterized by osteomalacia and hypophosphatemia in adult pa...

see more →

News  41 results

Burosumab Shows Sustained Efficacy in Rare Inherited Rickets
https://www.medscape.com/viewarticle/919315

Oct 1st, 2019 - ORLANDO, Florida — Burosumab (Crysvita, Ultragenyx), an anti-FGF23 monoclonal antibody, shows long-term safety and efficacy out to almost 2 years in the treatment of X-linked hypophosphatemia (XLH), a rare, inherited form of rickets, according to ...

2018 FDA-approved new drugs
https://www.mdedge.com/obgyn/article/197634/obstetrics/2018-fda-approved-new-drugs/page/0/1?channel=52

Mar 27th, 2019 - Antilipemic agents Crysvita (burosumab-twza), which has a MW of about 147,000, is a fibroblast growth factor–blocking antibody indicated for the treatment of X-linked hypophosphatemia. In pregnant cynomolgus monkeys, doses slightly higher than the.

FGF23 Inhibitor Effective in Rare Inherited Form of Rickets
https://www.medscape.com/viewarticle/904089

Oct 28th, 2018 - SAN DIEGO — For adults with X-linked hypophosphatemia (XLH), a rare inherited form of rickets, a monthly dose of burosumab (Crysvita, Kyowa Hakko Kirin and Ultragenyx Pharmaceutical) can normalize phosphorous levels and enhance bone mineralization...

FDA approves burosumab to treat X-linked hypophosphatemia
https://www.mdedge.com/familymedicine/article/163725/rare-diseases/fda-approves-burosumab-treat-x-linked-hypophosphatemia
Clinical Endocrinology News; Kari Oakes

Apr 18th, 2018 - The Food and Drug Administration has approved burosumab to treat X-linked hypophosphatemia, a rare, heritable form of rickets, in adults and children at least 1 year of age. Burosumab received expedited review by the FDA as a breakthrough therapy,.

FDA approves Ultragenyx's drug for rare form of rickets
https://www.reuters.com/article/us-ultragenyx-fda/fda-approves-ultragenyxs-drug-for-rare-form-of-rickets-idUSKBN1HO2NW

Apr 17th, 2018 - (Reuters) - The U.S. Food and Drug Administration has approved Ultragenyx Pharmaceutical Inc’s treatment for a rare and inherited form of rickets, a condition that causes weak bones, the agency said on Tuesday. California-based Ultragenyx’s shares...

see more →